X0508 4 2024-02-28 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001190279 RODRIGUEZ RAUL R RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true true CEO, President false Employee Stock Option (right to buy) 1.87 2024-02-28 4 A 0 300000 0 A 2033-01-26 Common Stock 300000 300000 D Employee Stock Option (right to buy) 1.27 2024-02-28 4 A 0 300000 0 A 2034-01-23 Common Stock 300000 300000 D The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. /s/ Raymond Furey (Attorney-in-Fact) 2024-03-01